SCHEMBL2089902

SCHEMBL2089902

COCCCc1ccco1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.49
HPGD P15428 4/20 0.49
CYP3A4 P08684 2/20 0.49
ALOX15 P16050 2/20 0.49
USP2 O75604 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
HSD17B10 Q99714 3/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 3/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TSHR P16473 2/20 0.40
POLB P06746 1/20 0.40
ALOX12 P18054 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2097627 0.94 ALDH1A1 (0.51) ALDH1A1HPGDCYP3A4ALOX15USP2
SCHEMBL5133452 0.92 ALDH1A1 (0.54) ALDH1A1HPGDCYP3A4ALOX15USP2
SCHEMBL12015523 0.88
SCHEMBL27209689 0.83 ALDH1A1 (0.52) ALDH1A1HPGDCYP3A4ALOX15USP2
SCHEMBL11060991 0.80 ALDH1A1 (0.61) ALDH1A1HPGDCYP3A4ALOX15USP2
SCHEMBL7094868 0.80 ALDH1A1 (0.67) ALDH1A1HPGDCYP3A4ALOX15USP2
SCHEMBL2089899 0.80 ALDH1A1 (0.53) ALDH1A1HPGDCYP3A4ALOX15USP2
SCHEMBL7093157 0.78 ALDH1A1 (0.70) ALDH1A1HPGDCYP3A4ALOX15USP2
SCHEMBL20956691 0.78 ALDH1A1 (0.55) ALDH1A1HPGDCYP3A4ALOX15USP2
SCHEMBL2094639 0.77 ALDH1A1 (0.50) ALDH1A1HPGDCYP3A4ALOX15USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ALDH1A1 412/4885HPGD 1951/4885CYP3A4 1734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.